CINCINNATI, May 23, 2022
/PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a
leading global provider of diagnostic testing solutions and life
science raw materials, announced today its participation in
the 2022 H.C. Wainwright Global Investment Conference.
Jack Kenny, Chief Executive Officer,
will pre-record the company's presentation. A link to Mr.
Kenny's presentation will be posted on May
24, 2022, on the Meridian Bioscience website at
https://investor.meridianbioscience.com/news-events/events-presentations/,
and will be accessible for 90 days.
For additional information on the 2022 H.C. Wainwright Global
Investment Conference, please visit
www.hcwevents.com/globalconference/.
About Meridian Bioscience, Inc.
Meridian
is a fully integrated life science company that develops,
manufactures, markets, and distributes a broad range of innovative
diagnostic products. We are dedicated to developing and delivering
better solutions that give answers with speed, accuracy, and
simplicity that are redefining the possibilities of life from
discovery to diagnosis. Through discovery and development, we
provide critical life science raw materials used in immunological
and molecular tests for human, animal, plant, and environmental
applications. Through diagnosis, we provide diagnostic solutions in
areas including gastrointestinal and upper respiratory infections
and blood lead level testing. We build relationships and provide
solutions to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics
manufacturers, and biotech companies in more than 70 countries
around the world.
Meridian's shares are traded on the NASDAQ Global Select Market,
symbol VIVO. Meridian's website address is
www.meridianbioscience.com.
Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/meridian-bioscience-to-participate-in-the-2022-hc-wainwright-global-investment-conference-301553073.html
SOURCE Meridian Bioscience, Inc.